Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;6(1):61-70.
doi: 10.2217/cns-2016-0013. Epub 2016 Dec 21.

Treatment options for recurrent high-grade gliomas

Harjus S Birk  1 , Seunggu J Han  1 , Nicholas A Butowski  1
Affiliations
Review

Treatment options for recurrent high-grade gliomas

Harjus S Birk et al. CNS Oncol. 2017 Jan.

Abstract

High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.

Keywords: glioblastoma; high-grade gliomas; overall survival; progression-free survival; recurrence treatment.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

No writing assistance was utilized in the production of this manuscript.

References

    1. Pranckeviciene A, Bunevicius A. Depression screening in patients with brain tumors: a review. CNS Oncol. 2015;4(2):71–78. - PMC - PubMed
    1. Apuzzo MLJ. Malignant Cerebral Glioma. American Association of Neurological Surgeons; Park Ridge, USA: 1990. pp. 79–89.
    1. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683–2710. - PubMed
    1. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer. 2007;110(1):13–24. - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352(10):987–996. - PubMed

    2. •• Seminal article describing the establishment of a standard treatment for glioblastoma (GB) consisting of concomitant chemoradiotherapy with temozolomide (TMZ) followed by 6–12 cycles of adjuvant TMZ.

MeSH terms

LinkOut - more resources